Industry Report

The global stem cell market is estimated at $15.10 billion in 2024 and is projected to nearly double to $28.89 billion by 2030, growing at a compound annual growth rate of 11.4 percent. This growth is driven by advances in regenerative medicine, increasing investments, and new therapies targeting serious diseases such as cancer, autoimmune disorders,… Continue reading Four Rising Stars Driving the Next Wave of Stem Cell and Gene Therapy Innovation (AIDA, MESO, LCTX, CRSP)

The U.S. Department of Defense (DoD) is throwing its financial weight around in 2025, unleashing a spending spree that’s lighting up the markets and positioning companies like Draganfly Inc. (NASDAQ: DPRO | CSE: DPRO), MP Materials Corp. (NYSE: MP), Rare Resource Recycling Inc., Military Metals Corp. (OTCQB: MILIF | CSE: MILI), and Perpetua Resources Corp.… Continue reading The Pentagon’s 2025 Push: A Spending Spree To Fortify America’s Critical Minerals and Tech, (DPRO, MP, MILIF, PPTA)

The U.S. drone industry may be entering a pivotal phase of growth, driven by new federal policies aimed at accelerating domestic innovation and deployment. On July 11, 2025, the Department of Defense announced a major initiative to rapidly expand the use of small, low-cost drones across military units. This move follows a recent executive order… Continue reading Federal Policy Shift Puts U.S. Drone Stocks on the Flight Path to Growth (ZENA, AVAV, KTOS, ONDS)

Now that the SPDR S&P Biotech index is displaying signs of renewed strength, the biotech boom could resume. In the past three months alone, the index has soared by 23% due to a number of factors, such as an increase in high-profile acquisitions and President Trump’s decisions to delay tariffs for drug imports. With the… Continue reading Medicus Pharma Ltd. (NASDAQ:MDCX): Novel Pipeline Presents Unique Opportunity To Capitalize On Rare Disease Market Worth Over $15 Billion

The global oncology drug market is currently valued at over 200 billion dollars and is expected to more than double to 532 billion dollars by 2031. This growth is driven not only by rising demand but also by genuine innovation. After years of steady but incremental progress, newer therapies such as antibody drug conjugates and… Continue reading OS Therapies Inc. (NYSE-A: OSTX) Makes Important Strides in Rare Cancer Therapy

The One Big Beautiful Bill, also known as H.R. 1, was signed into law by President Trump on July 4, 2025. It delivers one of the largest federal investment packages in recent memory, combining permanent tax changes with over $150 billion in new defense spending and another $150 billion for border security, ICE, and related… Continue reading $33 Billion for Drones: How the One Big Beautiful Bill Creates a New Defense Boom (ZENA, KTOS, AVAV, LHX)

Regenerative medicine is gaining serious momentum in 2025 as scientific advances, regulatory progress, and payer acceptance converge to push the sector into a new growth phase. The global regenerative medicine market, valued at nearly $28 billion in 2024, is projected to grow at over 16% annually through 2030, driven by rising demand for cell and gene therapies… Continue reading Small Caps, Big Potential: Regenerative Medicine Stocks Positioned for Growth

Biotech is entering a new phase of growth in summer 2025, backed by scientific momentum, clinical progress, and a more favorable investment landscape. Following a challenging few years, the sector is rebounding as interest rates ease and investors return to innovative, high-conviction names with late-stage programs and differentiated platforms. New technologies are accelerating timelines across… Continue reading Biotech’s Turning Point: 4 Stocks Poised to Ride the 2025 Wave (MDCX, ACTU, CRBU, NMRA)